Phase I Study of ADI-PEG20 Plus Low-Dose Cytarabine for the Treatment of Acute Myeloid Leukemia [PDF]
Cancer Medicine, 2021 Most acute myeloid leukemia (AML) cells are argininosuccinate synthetase‐deficient. Pegylated arginine deiminase (ADI‐PEG20) monotherapy depletes circulating arginine, thereby selectively inducing tumor cell death.
Hui-Jen Tsai, Tsai-Yun Chen, Ya-Ting Hsu
exaly +3 more sources
Citrulline and ADI-PEG20 Reduce Inflammation in a Juvenile Porcine Model of Acute Endotoxemia [PDF]
Frontiers in ImmunologyBackgroundArginine is a conditionally essential amino acid that is depleted in critically ill or surgical patients. In pediatric and adult patients, sepsis results in an arginine-deficient state, and the depletion of plasma arginine is associated with ...
Mahmoud A Mohammad +2 more
exaly +4 more sources
Arginine Deprivation/Citrulline Augmentation With ADI-PEG20 as Novel Therapy for Complications in Type 2 Diabetes [PDF]
Molecular MetabolismObjective: Chronic inflammation and oxidative stress mediate the pathological progression of diabetic complications, like diabetic retinopathy (DR), peripheral neuropathy (DPN) and impaired wound healing.
Ammar Abdelrahman +2 more
exaly +4 more sources
Overcoming resistance to arginine deprivation therapy using GC7 in pleural mesothelioma [PDF]
iScienceSummary: Pleural mesothelioma is a highly chemotherapy-resistant cancer. Approximately 50% of mesotheliomas do not express argininosuccinate synthetase 1 (ASS1), the rate-limiting enzyme in arginine biosynthesis, making arginine depletion with pegylated ...
Josephine Carpentier +6 more
doaj +2 more sources
Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers [PDF]
iScienceSummary: Aggressive-variant prostate cancers (AVPCs) respond poorly to anti-androgen therapy but show sensitivity to taxane-platinum chemotherapy, though outcomes remain poor.
Elavarasan Subramani +31 more
doaj +2 more sources
A Role for Macrophages Under Cytokine Control in Mediating Resistance to ADI-PEG20 (Pegargiminase) in ASS1-Deficient Mesothelioma [PDF]
Pharmacological Reports, 2023 Peter Szlosarek +2 more
exaly +2 more sources
Therapeutic potential of arginine deprivation therapy for gliomas: a systematic review of the existing literature [PDF]
Frontiers in PharmacologyBackgroundArginine deprivation therapy (ADT) hinders glioma cells’ access to nutrients by reducing peripheral blood arginine, showing great efficacy in various studies, which suggests it as a potentially promising treatment for glioma.
Chen Yuxiao +7 more
doaj +2 more sources
A Phase 1 Study of ADI-PEG20 (Pegargiminase) Combined With Cisplatin and Pemetrexed in ASS1-Negative Metastatic Uveal Melanoma [PDF]
Pigment Cell and Melanoma Research, 2022 Pui Ying Chan +2 more
exaly +2 more sources
Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment [PDF]
Clinical Cancer Research, 2023 Carina Dehner +2 more
exaly +2 more sources
Phase 1 Trial of ADI-PEG20 Plus Cisplatin in Patients With Pretreated Metastatic Melanoma or Other Advanced Solid Malignancies [PDF]
British Journal of Cancer, 2021 Aung Naing, Siqing Fu, Ahmed S Kaseb
exaly +2 more sources